4//SEC Filing
Bredt David 4
Accession 0000950170-25-109838
CIK 0002012593other
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 5:14 PM ET
Size
7.1 KB
Accession
0000950170-25-109838
Insider Transaction Report
Form 4
Bredt David
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-08-15$15.79/sh−200$3,158→ 426,642 total - Sale
Common Stock
2025-08-15$14.98/sh−8,300$124,308→ 426,842 total
Footnotes (3)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.74 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Documents
Issuer
Rapport Therapeutics, Inc.
CIK 0002012593
Entity typeother
Related Parties
1- filerCIK 0002022087
Filing Metadata
- Form type
- 4
- Filed
- Aug 17, 8:00 PM ET
- Accepted
- Aug 18, 5:14 PM ET
- Size
- 7.1 KB